MetaCap

Greenwich LifeSciences (GLSI) vs Vicore Pharma AB (VCRE)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Greenwich LifeSciences is the larger company by market cap ($282.6 million vs $264.9 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

GLSI-5.82%VCRE-42.12%
+3%-23%-49%
Jul 6, 20261 yearNov 20, 2026
GLSI-2.78%VCRE-31.75%
+2%-17%-37%
Jul 6, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

GLSI versus VCRE key metrics
MetricGLSIVCRE
Share price$19.25$9.41
Market cap$282.56M$264.89M
1-day change-2.73%-5.09%
YTD return-8.38%—
1-year return+136.20%—
5-year return-41.84%—
EPS (TTM)$-1.63$-2.04
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-19.36M—
52-week high$34.10$17.80
52-week low$7.78$7.88
Distance from 52-week high-43.55%-47.16%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+198.70%+158.90%
Average volume160.76K23.31K
Shares outstanding14.68M28.16M
Employees—50
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Greenwich LifeSciences

GLSI stock →

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States. Its lead product candidate is GP2, a HER2/neu transmembrane peptide, which is in Phase III clinical trial to prevent breast cancer recurrences in patients.

Health Care · Biotechnology: Pharmaceutical Preparations

About Vicore Pharma AB

VCRE stock →

Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden. The company develops Buloxibutid (C21), an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial for treating pulmonary hypertension.

Health Care · Biotechnology: Pharmaceutical Preparations · 50 employees

GLSI vs VCRE FAQ

Which is bigger, Greenwich LifeSciences or Vicore Pharma AB?

Greenwich LifeSciences (GLSI) is larger, with a market capitalization of $282.56M compared with $264.89M for Vicore Pharma AB (VCRE).

Are Greenwich LifeSciences and Vicore Pharma AB in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons